Uplizna reduces immune B-cell subsets linked to disease activity
Uplizna reduces several subsets of immune B-cells that are linked to relapses in people with neuromyelitis optica spectrum disorder, data show.| Neuromyelitis News
Uplizna reduces several subsets of immune B-cells that are linked to relapses in people with neuromyelitis optica spectrum disorder, data show.| Neuromyelitis News
Uplizna prevented autoimmune attacks in people with neuromyelitis optica spectrum disorder who received the treatment for four years or more.| Neuromyelitis News
Uplizna safely provided sustained disease control for NMOSD patients, according to final data from a Phase 2/3 clinical trial.| Neuromyelitis News
